Chemomab Therapeutics (CMMB) Total Non-Current Liabilities (2018 - 2025)
Chemomab Therapeutics (CMMB) posted Total Non-Current Liabilities of $179000.0 for Q1 2025, down 14.35% on a QoQ basis from $209000.0 in Q4 2024, and down 36.07% year-over-year from $280000.0 in Q1 2024.
Chemomab Therapeutics (CMMB) Total Non-Current Liabilities (2018 - 2025) Analysis & Trends
Chemomab Therapeutics' Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $179000.0 for Q1 2025.
- Quarterly Total Non-Current Liabilities fell 36.07% year-over-year to $179000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $179000.0 (down 36.07% YoY) and the FY2024 annual result came in at $209000.0, down 33.86% from the prior year.
- Total Non-Current Liabilities was $179000.0 for Q1 2025 at Chemomab Therapeutics, down from $209000.0 in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $328000.0 in Q1 2021 and bottomed at $5000.0 in Q3 2023.
- A 5-year average of $194588.2 and a median of $209000.0 in 2024 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities sank 95.76% — and 2024, when it jumped 4500.0%.
- Chemomab Therapeutics' Total Non-Current Liabilities stood at $237000.0 in 2021, then slumped by 61.6% to $91000.0 in 2022, then jumped by 247.25% to $316000.0 in 2023, then sank by 33.86% to $209000.0 in 2024, then dropped by 14.35% to $179000.0 in 2025.
- Business Quant data shows CMMB's Total Non-Current Liabilities at $179000.0 in Q1 2025, $209000.0 in Q4 2024, and $230000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Chemomab Therapeutics | 124.14 Mn | 113.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 179,000.00 |
| Dec 31, 2024 | 209,000.00 |
| Sep 30, 2024 | 230,000.00 |
| Jun 30, 2024 | 251,000.00 |
| Mar 31, 2024 | 280,000.00 |
| Dec 31, 2023 | 316,000.00 |
| Sep 30, 2023 | 5,000.00 |
| Jun 30, 2023 | 33,000.00 |
| Mar 31, 2023 | 62,000.00 |
| Dec 31, 2022 | 91,000.00 |
| Sep 30, 2022 | 118,000.00 |
| Jun 30, 2022 | 148,000.00 |
| Mar 31, 2022 | 203,000.00 |
| Dec 31, 2021 | 237,000.00 |
| Sep 30, 2021 | 298,000.00 |
| Jun 30, 2021 | 320,000.00 |
| Mar 31, 2021 | 328,000.00 |
| Dec 31, 2020 | 358,000.00 |
| Dec 31, 2019 | 725,000.00 |
| Sep 30, 2019 | 6.26 Mn |